Phathom Pharmaceuticals, Inc.
$13.47
▲
1.8%
2026-04-21 08:50:00
www.phathompharma.com
NMS: PHAT
Explore Phathom Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.04 B
Current Price
$13.47
52W High / Low
$18.31 / $2.21
Stock P/E
—
Book Value
$-6.13
Dividend Yield
—
ROCE
-125.87%
ROE
63.97%
Face Value
—
EPS
$-3.03
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
371
Beta
0.61
Debt / Equity
-0.48
Current Ratio
1.73
Quick Ratio
1.69
Forward P/E
8.18
Price / Sales
5.73
Enterprise Value
$1.45 B
EV / EBITDA
-9.13
EV / Revenue
8.31
Rating
Strong Buy
Target Price
$23.7
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Armata Pharmaceuticals, Inc. | $12.5 | — | $421.28 M | — | -45.96% | 130.37% | $16.34 / $1.11 | $-6 |
| 2. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 3. | Psyence Biomedical Ltd. | $11.3 | 30.05 | $7.77 M | — | -54.49% | -74.29% | $468.38 / $1.92 | $39.62 |
| 4. | Kezar Life Sciences, Inc. | $7.29 | — | $53.74 M | — | -74.59% | -59.93% | $7.55 / $3.53 | $9.56 |
| 5. | SeaStar Medical Holding Corporation | $4.63 | — | $16.77 M | — | -116.89% | -2.95% | $13.4 / $2.07 | $2.71 |
| 6. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 7. | Summit Therapeutics Inc. | $24.32 | — | $18.91 B | — | -161.37% | -2.06% | $36.91 / $13.83 | $0.85 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 57.58 M | 49.5 M | 39.5 M | 28.52 M | 29.66 M |
| Operating Profit | -5.93 M | -15.27 M | -59.92 M | -78.86 M | -59.42 M |
| Net Profit | -21.15 M | -29.97 M | -75.81 M | -94.32 M | -74.45 M |
| EPS in Rs | -0.27 | -0.38 | -0.95 | -1.19 | -0.94 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 175.11 M | 55.25 M | 0.68 M | 0 M |
| Operating Profit | -159.99 M | -277.47 M | -167.31 M | -172.44 M |
| Net Profit | -221.25 M | -334.33 M | -201.59 M | -197.72 M |
| EPS in Rs | -2.79 | -4.21 | -2.54 | -2.49 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 259.15 M | 378.32 M | 413.84 M | 164.81 M |
| Total Liabilities | 697.32 M | 631.9 M | 486.6 M | 239.62 M |
| Equity | -438.17 M | -253.58 M | -72.76 M | -74.81 M |
| Current Assets | 228.97 M | 360.13 M | 397.43 M | 160.51 M |
| Current Liabilities | 132.04 M | 85.73 M | 38.78 M | 26.24 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -166.78 M | -266.77 M | -137.58 M | -146.53 M |
| Investing CF | -0.23 M | -0.14 M | -1.63 M | -1.04 M |
| Financing CF | -0.29 M | 182.77 M | 367.58 M | 120.04 M |
| Free CF | -167 M | -266.9 M | -139.21 M | -147.57 M |
| Capex | -0.23 M | -0.14 M | -1.63 M | -1.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 8001.47% | — | — | — |
| Earnings Growth % | -65.84% | -1.96% | — | — |
| Profit Margin % | -605.09% | -29558.94% | — | — |
| Operating Margin % | -502.18% | -24532.55% | — | — |
| Gross Margin % | 85.57% | 75.51% | — | — |
| EBITDA Margin % | -473.33% | -23320.97% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.